2. • R & D of products galenics
• Manufacturing of own medicines in accordance
with Good manufacturing practices (GMP)
produce by belgian highly specialised
companies : LABIMA- WOLFS- STEROP
• High level product quality,
• High standards manufacturing process,
• Strict quality control by LCA ( laboratoire de contrôle des
analyses)
• Distribution and commercialisation in CIS
countries

3. Distribute at affordable prices Belgian and
European high quality medicines in our CIS
market in accordance to the Good Distribution
Practices (GDP)

4. 1983: Creation of the company by the
Pharmacist Eric Vandecauter.

5. 1992: The company participates to a fair in
Kiev. It’s the begining of the success story.
• Contracts are signed with local
administrations of DOMBASS
(Donietsk, Artemsol,Lugansk,…)
• Creation of the Kiev office

7. Creation of several offices
• 1993: Azerbaidjan and Uzbekistan
» Partnership starts with
• 1994: Moldova
• 1995: Kazakstan and Kyrghystan
• 1997: Georgia
• 2005: Armenia
• 2008: Turkmenistan and Tadjikistan
• Near future: Mongolia

8. • 1992: we start with:
– Bronchobru
– Diclobru tablets and ampoules
– Spasmobru tablets and ampoules
– Soptrimbru
– Bruambutol
– Pyrazinabru
– Rifampicine

12. General
manager
Olena Voshkulat
Sales Manager
Svetlana Avrinskaya
Marketing Manager
Elina Isaeva
Field force & scientific
managers
Pr Igor Kirehev
Pr Volodimir Kunovski
Regulatory
affairs
Kiev headquarter
Georgia 1 head representative 4 med reps
Armenia 1 head representative 4 med reps
Azerbaidjan 1 head representative
Kazakstan 1 head representative 5 med reps
Tadjikistan 1 head representative 2 med reps
Turkmenistan 1 head representative 1 med reps
Kyrghystan 1 head representative 1 med reps
Uzbekistan 1 med reps
Localrepresentations

13. • Regular trainings for the team members
• Participations to scientific conferences
• Organize and structure medical and Pharmacies delegation
• Registrations of medicines for us and third party (regulatory
affairs)
• Monthly scientific comitee
 +- 10 publications yearly
• Sponsoring of key opinion leaders for participation into
international congress (DDW & ESPAGHAN)
• Annual international meeting for all members of the
company

14. 0
1,000,000
2,000,000
3,000,000
4,000,000
5,000,000
6,000,000
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
CIS
CIS